Mereo BioPharma Group PLC (MREO)
2.74
-0.07
(-2.49%)
USD |
NASDAQ |
Apr 26, 16:00
2.745
0.00 (0.00%)
After-Hours: 20:00
Mereo BioPharma Group Cash from Financing (TTM): 7.973M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.973M |
| June 30, 2023 | -0.6012M |
| December 31, 2022 | 0.20M |
| June 30, 2022 | -3.516M |
| December 31, 2021 | 104.80M |
| June 30, 2021 | 94.31M |
| December 31, 2020 | 47.34M |
| June 30, 2020 | 57.82M |
| Date | Value |
|---|---|
| December 31, 2019 | -7.487M |
| June 30, 2019 | -5.950M |
| December 31, 2018 | -2.633M |
| June 30, 2018 | 26.04M |
| December 31, 2017 | 45.60M |
| June 30, 2017 | 11.53M |
| December 31, 2016 | 84.34M |
| June 30, 2016 | 91.38M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-7.487M
Minimum
Dec 2019
104.80M
Maximum
Dec 2021
29.49M
Average
4.086M
Median
Cash from Financing (TTM) Benchmarks
| Adaptimmune Therapeutics PLC | 0.88M |
| Biodexa Pharmaceuticals Plc | 12.76M |
| NuCana PLC | -0.0659M |
| TC BioPharm (Holdings) PLC | 10.62M |
| Autolus Therapeutics PLC | -0.883M |